MuSK antibody-positive, seronegative myasthenia gravis in Korea

被引：28
作者：
Lee, JY
Sung, JJ
Cho, JY
Oh, DH
Kim, HJ
Park, JH
Lee, KW
Choi, YC
Vincent, A
机构：
[1] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Neurol, Seoul 110744, South Korea
[2] Seoul Natl Univ, Boramae Hosp, Dept Neurol, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Clin Res Inst, Seoul 110744, South Korea
[4] Yonsei Univ, Coll Med, Young Dong Severance Hosp, Dept Neurol, Seoul, South Korea
[5] John Radcliffe Hosp, Inst Mol Med, Neurosci Grp, Oxford OX3 9DU, England
来源：
JOURNAL OF CLINICAL NEUROSCIENCE | 2006年 / 13卷 / 03期
关键词：
MuSK; myasthenia gravis; Korea;
D O I：
10.1016/j.jocn.2005.04.028
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Several reports from Western countries suggest differences in the clinical features of patients with muscle specific kinase (MuSK) antibody-positive and -negative seronegative myasthenia gravis (MG). We performed the first survey in Korea of MuSK antibodies, studying 23 patients with acetylcholine receptor (AChR)-antibody seronegative MG. MuSK antibodies were present in 4 (26.7%) of 15 generalized seronegative MG patients and none of 8 ocular seronegative MG patients. All four MuSK positive patients were females, with pharyngeal and respiratory muscle weakness, and required immunosuppressive treatment. However, overall disease severity and age at onset was similar to that of MuSK-negative MG and treatment responses were equally good. (C) 2006 Published by Elsevier Ltd.
引用
收藏
页码：353 / 355
页数：3
相关论文
共 12 条
[1]   The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo [J].
DeChiara, TM ;
Bowen, DC ;
Valenzuela, DM ;
Simmons, MV ;
Poueymirou, WT ;
Thomas, S ;
Kinetz, E ;
Compton, DL ;
Rojas, E ;
Park, JS ;
Smith, C ;
DiStefano, PS ;
Glass, DJ ;
Burden, SJ ;
Yancopoulos, GD .
CELL, 1996, 85 (04) :501-512
[2]   Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis [J].
Evoli, A ;
Tonali, PA ;
Padua, L ;
Lo Monaco, M ;
Scuderi, F ;
Batocchi, AP ;
Marino, M ;
Bartoccioni, E .
BRAIN, 2003, 126 :2304-2311
[3]   Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies [J].
Hoch, W ;
McConville, J ;
Helms, S ;
Newsom-Davis, J ;
Melms, A ;
Vincent, A .
NATURE MEDICINE, 2001, 7 (03) :365-368
[4]   Myasthenia gravis - Recommendations for clinical research standards [J].
Jaretzki, A ;
Barohn, RJ ;
Ernstoff, RM ;
Kaminski, HJ ;
Keesey, JC ;
Penn, AS ;
Sanders, DB .
NEUROLOGY, 2000, 55 (01) :16-23
[5]   A treatment algorithm for autoimmune myasthenia in adults [J].
Keesey, J .
MYASTHENIA GRAVIS AND RELATED DISEASES: DISORDERS OF THE NEUROMUSCULAR JUNCTION, 1998, 841 :753-768
[6]  
KIM JS, 1996, J KOREAN NEUROL ASS, V14, P206
[7]  
Lee KW, 1997, J KOREAN NEUROL ASS, V15, P825
[8]   The agrin/muscle-specific kinase pathway: New targets for autoimmune and genetic disorders at the neuromuscular junction [J].
Liyanage, Y ;
Hoch, W ;
Beeson, D ;
Vincent, A .
MUSCLE & NERVE, 2002, 25 (01) :4-16
[9]   Treatment of autoimmune myasthenia gravis [J].
Richman, DP ;
Agius, MA .
NEUROLOGY, 2003, 61 (12) :1652-1661
[10]   Clinical aspects of MuSK antibody positive seronegative MG [J].
Sanders, DB ;
El-Salem, K ;
Massey, JM ;
McConville, J ;
Vincent, A .
NEUROLOGY, 2003, 60 (12) :1978-1980
12